BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

PROGRAM

2022 Conference Agenda

​​

BIO Asia–Taiwan 2022
Conference Agenda 

Date July 27-29, 2022

Venue TaiNEX2, Taipei + Online event platform

Day 1 - Wednesday, July 27
Day 2 - Thursday, July 28
Day 3 - Friday, July 29
09:00 – 09:05

Welcome

Johnsee Lee, Chairman of BIO Asia–Taiwan 2021
09:05 – 09:10

VIP Remarks

Michelle McMurry-Heath, President and CEO, Biotechnology Innovation Organization (BIO)
09:10 – 09:15

VIP Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
09:15 – 09:35

Opening Address

Government Representative
09:35 – 09:50

Keynote Speech- Top iPS Cell Technologies at Affordable Prices

Shinya Yamanaka M.D., Ph.D., Nobel Prize Laureate 
Representative Director, CiRA Foundation
09:50 – 10:05

Bioconvergence: Potential Future Impacts to Personalized Medicine

Laura Matz, Chief Science & Technology Officer at Merck KGaA
10:05 – 10:20

The ‘New Normal’: transforming healthcare and implications for Pharma

Graham Lewis, Vice President Global Pharma Strategy, IQVIA
10:20 – 10:35

Future of Health – How to transform BioPharma for the upcoming LIFEcare system

Thomas Solbach, Partner and Europe Pharma & Life Science Leader, PwC Strategy& (Germany) GmbH
10:40 – 10:55

A Dynamic Global Supply Chain with Policy Consideration (TBD)

John A. Murphy, III, Chief Policy Officer Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO)
10:55 – 11:10

2022 Health Trends: Appropriate Acceleration in Clinical Development

Ken J. Lee, General Manager and Region Head, Asia Pacific, Syneos Health
11:10 – 11:25

New Horizons for Silicon Nanotechnology in Healthcare

Paru Deshpande, Vice President R&D, imec
11:25 – 11:40

Genomics England: Enabling the Next Chapter of the UK’s Contribution in Genomics

Chris Wigley, Chief Executive Officer, Genomics England
11:40 – 12:10

Panel Discussion and Comments

12:20 – 12:25

Opening Remarks

Henry Chen, President, IRPMA
12:25 – 12:35

Clinical Trial Ecosystem

Mick Stanley, General Manager, GlaxoSmithKline Taiwan
12:35 – 12:45

Collaboration between Pharma and Technology Companies on Digital Health - The Power of Cross-industry Partnering

Jorge Wagner, General Manager & Country President, Novartis Taiwan
12:45 – 12:55

How MNCs Support Taiwan for its Precision Medicine Development?

Cellina Yeh, Country Manager, Pfizer Taiwan
12:55 – 13:40

Panel Discussion

Moderator:
  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2022
Panelists:
  • TBC
13:40 – 13:50

Closing Remarks

Ramanathan Velayutham, Standing Director, IRPMA
14:00 – 14:05

Opening Remarks

Joseph Chou, Chairman and CEO, PwC Taiwan
14:05 – 15:30

Panel Discussion

Moderator:
  • Timothy K. Lu, Co-founder & CEO, Senti Biosciences
Panelists:
  • Seth Lieblich, Principle, 8VC
  • Eckard Weber, Venture Partner, Canaan Partners / Advisory Partner, Domain Associates
  • Dennis Podlesak, CEO and Managing Partner, Canaan Partners’ Axceliux
  • Portia Ku, Partner, O'Melveny
  • George Yeh, President, TLC Biosciences
14:00 – 14:05

Opening Remarks

Chung-Hsiun Wu, President, Development Center for Biotechnology
14:05 – 14:20

Delivering on the next mRNA-based breakthroughs

Kathy Fernando, Vice President, Head of mRNA Scientific Strategy, Pfizer
14:20 – 14:35

Topic TBD

Speaker Inviting
14:35 – 14:50

mRNA -based therapeutics, Opportunities and Challenges-Manufacturing Area (TBD)

Tracy Humphries, mRNA Segment Marketing Leader, Cytiva
14:50 – 15:05

Self-amplifying mRNA vaccines, a New Therapeutic Modality (TBD)

Wilber Huang, President, Abnova Corp. (Inviting)
15:05 – 15:20

Using Biomedical Data in Precision CAR-T Cell Technology Development

Tsai-Kun Li, Vice President, Development Center for Biotechnology
15:20 – 15:30

Closing Remarks

Chung-Hsiun Wu, President, Development Center for Biotechnology
09:00 – 10:30
Session 6 - BIO Asia–Taiwan 2022 Opening & Award Ceremony (By Invitation Only)
09:00 – 09:30

Admission

09:30 – 09:35

Introducing Honorable Guests

09:35 – 09:40

Welcome Remarks

​Johnsee Lee, Chairman of BIO Asia–Taiwan 2022
09:40 – 09:55

Opening Speech

Tsai Ing-wen, President, Taiwan (Inviting)
09:55 – 10:05

VIP Remarks

Michelle McMurry-Heath, President & CEO, Biotechnology Innovation Organization
10:05 – 10:20

2022 Taiwan BIO Awards Ceremony

10:20 – 10:30

Ribbon-cutting Ceremony

10:30

Adjourn

 
10:40 – 10:45

Opening Remarks

Hong-Chen Chen, Director General, Department of Life Sciences, Ministry of Science and Technology
10:45 – 11:05

Universal Vaccine Development

Chi-Huey Wong, Welch and Wolf Prize Laureate; Academician, Academia Sinica; Scripps Family Chair Professor of Chemistry, The Scripps Research Institute
11:00 – 11:15

Stopping the Next Pandemic Before It Starts

11:15 – 11:30

Post COVID-19 Pandemic Health Challenges: How to expedite such a trial for the treatment of COVID Long Haulers

Kazem Kazempour, President and CEO, Amarex Clinical Research
11:30 – 12:00

Panel Discussion: Readiness to Contain Pandemic-the Role of Industry with Public-Private Partnership

Moderator:
  • Hong-Chen Chen, Director General, Department of Life Sciences, MOST
Panelists:
  • Speakers of the session and additional Panelists form Industry
12:20 – 12:25

Welcome Remark

MOEA Representative
12:25 – 12:30

Opening Remarks

Dan Wang, Regional Head, Johnson & Johnson Innovation, Asia Pacific
12:30 – 12:45

BioTech Ecosystem in Taiwan + Janssen-Taiwan Grant Call Platform
Building a Sustainable BioTech Ecosystem with Taiwan

Chii-Wann Lin, Vice President and General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
12:45 – 13:15

Insights from J&J Innovation, JLABs, JJDC
Integrating Global Innovation Networks

Stephen Lee, Director, Early Innovation Partnering, North Asia, Johnson & Johnson Innovation, Asia Pacific
Sharon Chan, Head of JLABS @ Shanghai, Johnson & Johnson Innovation
Wei Wu, PhD, Principal, Johnson & Johnson Innovation – JJDC
13:15 – 13:50

Panel Discussion: Accelerating Innovation Through External Collaboration

Moderator: 
  • Stephen Lee, Director, Early Innovation Partnering, North Asia, Johnson & Johnson Innovation, Asia Pacific
Panelists:
  • Andrew Wong, VP Transactions & Early Innovation Partnering, Johnson & Johnson Innovation, Asia Pacific
  • Ming-Kuei Jang, CEO, Aprinoia (JLABS@Shanghai resident)
  • Chi-Chun (Jeremy) Lee, Professor, National Tsing Hua University (NTHU)
  • Hsing-chen Tsai, Principal Investigator, Internal Medicine Department, National Taiwan University Hospital (NTUH)
  • Kang-Li Wang, Associate Researcher, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
14:00 – 14:03

Opening Remarks

Michael Huang, Managing Partner, Bio Fund
Taiwania Capital Management Corp.
14:03 – 14:18

Why Adoption Strategy is Critical to Digital Health?

Lenny Chen, Executive Consultant, Presentality
14:18 – 14:33

Bridging the Gap between Academia and Commercialization: From the Healthcare Perspective

Yu Chuan Jack Li, Distinguished Professor, Graduate Institute of Biomedical Informatics, Taipei Medical University
14:33 – 14:48

The Common Misconception of ICT in Healthcare

Jerry Chang, President, FaceHeart Corporation
14:48 – 15:27

Panel Discussion: How Do We Survive and Thrive?

Moderator:
Victoria Wang, Principal, Bio Fund
Taiwania Capital Management Corp.

Panelists:
Jim Long, Co-Founder & Chief Executive Officer, AESOP Technology
Tien-Jen Liu, MD, Co-Founder & Chief Operating Officer, AIXMED Inc.
Jerry Chang, President, FaceHeart Corporation
Ed Deng, Co-Founder & Chief Executive Officer, Health2Sync
15:27 – 15:30

Closing Remarks

Michael Huang, Managing Partner, Bio Fund
Taiwania Capital Management Corp.
15:40 – 15:45

Opening Remarks

Huey-Kang Sytwu, Vice President, National Health Research Institutes
15:45 – 16:00

Managing Trial Planning and Design with Artificial Intelligence

Aparajeeta Priyadarasini, Manager, Solution Consulting, Medidata
16:00 – 16:15

Topic TBD

Syneos Health
16:15 – 16:30

Investment Trends in Digital Health

Chia-Jui Su, Head of Healthcare and Life Science, KPMG in Taiwan
16:30 – 16:45

Artificial Intelligence Advanced Precision Medicine for Metabolic Diseases

Ting-Fen Tsai, Professor, Department of Life Sciences and Institute of Genome Sciences in National Yang Ming Chiao Tung University
16:45 – 17:00

Data insights: Along the patient journey

Sylvia Wong, Customer Success Manager, Roche Diagnostic
17:00 – 17:10

Closing Remarks

​Huey-Kang Sytwu, Vice President, National Health Research Institutes
09:00 – 09:05

Opening Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
09:05 – 09:20

Synthetic Biology (TBD)

Timothy K. Lu, Associate Professor of MIT Biological Engineering and Electrical Engineering and Computer Science
09:20 – 09:40

Preemptive Genetic Profiling for Drug Development and Health Management

Pui-Yan Kwok, Distinguished Research Fellow and Director, Institute of Biomedical Sciences; Academician, Academia Sinica
09:40 – 10:00

1 Cell, 2 Weeks, 3D Culture to Find a Drug:
Single Cell 3D Culture Technology Accelerating Precision Medicine

Ying Chih Chang, Professor, Genomics Research Center, Academia Sinica; CEO, AcroCyte Therapeutics
10:00 – 10:15

Machine Learning on Genomic Sequencing (TBD)

Tristan Bepler, Group Leader, Simons Machine Learning Center, New York Structural Biology Center; Co-Founder and CEO of OpenProtein.AI
10:15 – 10:30

Conclusion Remarks

Jung-Hsin Lin, Research Fellow/Deputy Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
Closing Remarks

Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
10:40 – 10:42

Opening Remarks

Lee-Cheng Liu, Dr.Sci.Eng., Founder, Chairman and President of EirGenix, Inc.
10:42 – 11:02

Antibody Drug Conjugates (ADCs): 
Decades of study, successful product developments and a resurgence of interest

John M. Lambert, PhD, John Lambert Consulting, formal Executive VP Emeritus & Distinguished Research Fellow
11:02 – 11:22

Continuous Bio-processing(TBD)

Christopher Hwang, PhD, Executive Vice President, Chief Technology Officer at Transcenta
11:22 – 11:42

New Transformational Technologies for High-Quality and Cost-Effective Viral Vector Production to Enable Gene Therapies Development

David Chang, PhD, CEO, WuXi Advanced Therapies
11:42 – 12:10

Panel Discussion

Moderator: Lee-Cheng Liu, Founder, Chairman and President of EirGenix, Inc.
Panelists:
  • Christopher Hwang, Executive Vice President, Chief Technology Officer at Transcenta
  • David Chang, CEO, WuXi Advanced Therapies
  • Panelists form Industry (TBD)
12:20 – 12:25

Opening Remarks

Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
12:25 – 12:40

Topic TBD

Joseph Liu, Commercial Head, Cell and Gene Therapy, Asia Pacific Region, Novartis
12:40 – 12:55

Promise Fulfilled? The next decade of cell, gene, and RNA therapies

William Xu, Medical Strategy Director, IQVIA
12:55 – 13:10

Topic

TBD
13:10 – 13:25

Topic TBD

Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
13:25 – 13:50

Panel Discussion


Moderator:
  • Kang-Yun Lee, Dean, Research and Development, Professor, Division of Thoracic Medicine, Taipei Medical University
Panelists:
  • Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
  • Susy Liang, President, Taiwan Hitachi Asia Pacific Co., Ltd. (Inviting)
  • Joseph Liu, Commercial Head, Cell and Gene Therapy, Asia Pacific Region, Novartis
  • William Xu, Medical Strategy Director, IQVIA (Inviting)
14:00 – 15:30

Panel Discussion

Moderator:

Jo Shen, Venture Partner, Vivo Capital

Panelists:

  • Edward Hsieh, VP, R&D, Formosa Lab
  • Bobby Sheng, Chairman, Bora
  • Roberto Gardellin, Global Health, Serializtion & EMG Risk Management Head - External Manufacturing Technical CoE, SMS & Digital, Sanofi
  • Vijay Sabesan, Sr. VP, Technical Operations, Kymera
  • Manuel Sanz, CFO/COO, Oncomatryx Biopharma
15:40 – 15:45

Opening Remarks

Johnsee Lee, Chairman, Precision Medicine Industry Association of Taiwan 
Liang-Gee Chen, Chairman, Taiwan Digital Health Industry Development Association
15:45 – 16:00

Building a Smart Cloud Computing Ecosystem for Healthcare

Barry Lam, Chairman & CEO, Quanta Group
16:00 – 16:15

Improving Patient Outcomes with Translating Technological Innovations and Science

Jessica L. Mega, MD, MPH, Chief Medical and Scientific Officer and Cofounder, Verily (Inviting)
16:15 – 16:30

Ubiquitous Healthcare Services in the Digital Era

Patrick Combes, Director, Head of Technology -Healthcare and Life Sciences at Amazon Web Services (AWS) (Inviting)
16:30 – 16:45

Integration of Biomolecular Sensor Technologies on a Silicon Platform

Pol Van Dorpe, Fellow of the Life Science Technologies Department, imec
16:45 – 18:00

Panel Discussion: Opportunities & Strategy When ICT Meets BIO

  • Johnsee Lee, Chairman, Precision Medicine Industry Association of Taiwan 
  • Liang-Gee Chen, Chairperson, Taiwan Digital Health Industry Development Association
  • Barry Lam, Chairman & CEO, Quanta Group
  • Pan-Chyr Yang, Academician, Academia Sinica
  • Andrew Lin, Chairman, TaiRx, Inc